Search Within

Thoracic Oncology

Formats
  1. Meeting Abstract (1709)
  2. Journal Article (1439)
  3. Review (82)
  4. Editorial (58)
  5. Book Section (35)
  6. Guidelines (25)
  7. Conference Paper (21)
  8. Correspondence (10)
  9. Research Letter (7)
  10. Miscellaneous (6)
  11. Book Whole (2)
Groups
  1. Department of Medicine (3394)
  2. Solid Tumor Oncology Division (3394)
  3. GSK Faculty (1071)
  4. Department of Pathology and Laboratory Medicine (809)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (662)
  6. Human Oncology and Pathogenesis Program (635)

More Groups

People
  1. Mark Kris (872)
  2. Alexander Drilon (637)
  3. Gregory Riely (605)
  4. Charles Rudin (495)
  5. Marc Ladanyi (418)
  6. Matthew Hellmann (412)

More People

Years
  1. 2025 (114)
  2. 2024 (271)
  3. 2023 (273)
  4. 2022 (337)
  5. 2021 (337)
  6. 2020 (258)

More Years

Publications
  1. Journal of Clinical Oncology (703)
  2. Journal of Thoracic Oncology (517)
  3. Annals of Oncology (278)
  4. Clinical Cancer Research (158)
  5. Cancer Research (128)
  6. International Journal of Radiation Oncology, Biology, Physics (89)

More Publications

Publishers
  1. American Society of Clinical Oncology (782)
  2. Elsevier Inc. (738)
  3. American Association for Cancer Research (386)
  4. Oxford University Press (352)
  5. Nature Publishing Group (156)
  6. Elsevier Science, Inc. (79)

More Publishers

Results (3394)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • HER2 mutations in lung adenocarcinoma: A report from the Lung Cancer Mutation Consortium (LCMC)
    Meeting Abstract

    Pillai, R. N.; Behera, M.; Berry, L. D.; Rossi, M. R.; Kris, M. G.; Bunn, P. A.; Khuri, F. R.; Ramalingam, S. S.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Phase I trial of the hedgehog (Hh) inhibitor, LDE225, in combination with etoposide and cisplatin (EP) for initial treatment of extensive stage small cell lung cancer (ES-SCLC)
    Meeting Abstract

    Pietanza, M. C.; Krug, L. M.; Varghese, A. M.; Fleisher, M.; Teitcher, J. B.; Holodny, A.; Sima, C. S.; Litvak, A. M.; Ng, K. K.; Patel, P. R.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC
    Meeting Abstract

    Pennell, N. A.; Neal, J. W.; Chaft, J. E.; Azzoli, C. G.; Jänne, P. A.; Govindan, R.; Evans, T. L.; Costa, D. B.; Rosovsky, R. P. G.; Wakelee, H. A.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • A phase 1b open-label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers: Preliminary antitumor activity and pharmacodynamic data
    Meeting Abstract

    Paik, P. K.; Shen, R. L.; Ferry, D.; Soria, J. C.; Mathewson, A.; Kilgour, E.; Landers, D.; Frewer, P.; Brooks, N.; André, F.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Stage IV large cell neuroendocrine carcinoma (LCNEC) of the lung: Clinicopathologic features, treatment, and survival
    Meeting Abstract

    Naidoo, J.; Woo, K.; Sima, C. S.; Rekhtman, N.; Thomas, S. B.; Sarkaria, I. S.; Rudin, C. M.; Krug, L. M.; Pietanza, M. C.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Multiarm, nonrandomized, open-label phase IB study to evaluate FP1039/GSK3052230 with chemotherapy in NSCLC and MPM with deregulated FGF pathway signaling
    Meeting Abstract

    Lopez, P. G.; Felip, E.; Delord, J. P.; Paz-Ares, L.; Grilley-Olson, J. E.; Gordon, M. S.; Barisal, F.; Arkenau, H. T.; Lara, P.; Paik, P. K.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes for patients with thymic carcinoma: Evaluation of Masaoka staging
    Meeting Abstract

    Litvak, A. M.; Woo, K.; Hayes, S. A.; Sima, C. S.; Huang, J.; Moreira, A. L.; Tsukazan, M. T. R.; Riely, G. J.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Vismodegib in the treatment of patients with metastatic basal cell carcinoma (mBCC) and distant metastases: Survival in the pivotal phase II and phase I studies
    Meeting Abstract

    Lewis, K. D.; Sekulic, A.; Hauschild, A.; Migden, M. R.; Oro, A. E.; LoRusso, P.; Rudin, C. M.; Dirix, L.; Solomon, J. A.; Hainsworth, J. D.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • NEOSCAN: Phase II trial of neoadjuvant chemotherapy for resectable lung cancers with switch to chemo alternative in (18)F-FDG PET nonresponders
    Meeting Abstract

    Kris, M. G.; Hellmann, M. D.; Naidoo, J.; Dunphy, M.; Sima, C. S.; Downey, R. J.; Travis, W. D.; Azzoli, C. G.; Chaft, J. E.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK plus ) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial
    Meeting Abstract

    Kim, D. W.; Mehra, R.; Tan, D. S. W.; Felip, E.; Chow, L. Q. M.; Camidge, D. R.; Vansteenkiste, J. F.; Sharma, S.; De Pas, T.; Riely, G. J.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save